This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2009 by Capital Medical University.
Recruitment status was:  Recruiting
Information provided by:
Capital Medical University Identifier:
First received: September 29, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted
The purpose of this study is to determine whether inhalation with aerosolized amphoterin B 10mg/d is more effective than aerosolized amphoterin B 2mg/d to reduce the incidence of invasive pulmonary aspergillosis.

Condition Intervention Phase
Invasive Pulmonary Aspergillosis Drug: Amphotericin B Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Capital Medical University:

Primary Outcome Measures:
  • invasive pulmonary aspergillosis [ Time Frame: 3 years ]

Estimated Enrollment: 400
Study Start Date: June 2008
Estimated Study Completion Date: October 2010
Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Amphotericin B
    Aerosolized Amphotericin B,2mg/day or 10mg/day

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 65ys≥age≥18ys
  • renal transplant recipients

Exclusion Criteria:

  • subjects with hypersensitivity to amphotericin B
  • receipt of inhalational or intravenous amphotericin B within last 30 days
  • subjects with known invasive fungal infection before renal transplant
  • subjects with pneumonia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00986713

China, Beijing
Beijing Chaoyang Hospital,Affiliate of Capital Medical University Recruiting
Beijing, Beijing, China, 100020
Contact: Bin Cao, doctor    8610-85231130   
Sponsors and Collaborators
Capital Medical University
  More Information

Responsible Party: Bin Cao,doctor, Beijing Chaoyang Hospital,Affiliate of Capital Medical Unibersity Identifier: NCT00986713     History of Changes
Other Study ID Numbers: CYH-CMU AmB Neph
Study First Received: September 29, 2009
Last Updated: September 29, 2009

Additional relevant MeSH terms:
Pulmonary Aspergillosis
Invasive Pulmonary Aspergillosis
Skin Diseases, Infectious
Skin Diseases
Lung Diseases, Fungal
Lung Diseases
Respiratory Tract Diseases
Amphotericin B
Liposomal amphotericin B
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Anti-Bacterial Agents
Antifungal Agents processed this record on September 21, 2017